Shilpa Medicare
SHILPAMED
Shilpa Medicare Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 4,32,870 |
| Weekly | 4.09% | 11,34,286 |
| Monthly | 16.98% | 79,04,638 |
Shilpa Medicare Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| SHILPAMED | - | 4.09% | 16.98% |
| Index | - | - | - |
| Peer Avg. | - | 5.43% | 11.51% |
Shilpa Medicare Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| SHILPAMED | 113.92 | 1.78 | 17.72 | 2.38 | 3.77 | 0.41 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Shilpa Medicare Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 32.99% | -63.80% | 2.38% | 3.77% |
| FY '20-21 | -34.43% | -33.35% | 7.31% | 7.70% |
| FY '19-20 | 22.60% | 33.52% | 12.27% | 12.75% |
Shilpa Medicare Shareholding Pattern
Shilpa Medicare Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 751.24 | 647.12 | 140.33 | 40.37 |
| FY '20-21 | 579.09 | 479 | 138.71 | 105.65 |
| FY '19-20 | 856.94 | 630.78 | 246.45 | 161.38 |
Shilpa Medicare Share Price
Shilpa Medicare Limited is an Indian pharmaceutical company. The company's field of activity is research and development, production and sale of oncology drugs and preparations. Its products consist of oncology and non-oncology active ingredients (APIs), oncology formulations, biosimilars, ophthalmic, orodispersible films, biochemical diagnostics, organic intermediates, testing and manufacturing scales, and transdermal patches. It provides oncology APIs and middleware. Its oncology/non-oncology APIs include capecitabine, gemcitabine hydrochloride, axitinib, erlotinib HCL and irinotecan HCL trihydrate in several regulated markets including the US, Europe, Japan, South Korea, Russia, Mexico, Brazil and other emerging markets. Its non-oncology API products include Ambroxol (a mucolytic agent) in Europe and Tranexamic Acid and Ursodeoxycholic Acid in India. The company also manufactures and sells Lenvatinib capsules under the Lenshil brand.